239 related articles for article (PubMed ID: 38104569)
21. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.
Vermeire S; D'Haens G; Baert F; Danese S; Kobayashi T; Loftus EV; Bhatia S; Agboton C; Rosario M; Chen C; Zhang W; Kisfalvi K; Sandborn WJ
J Crohns Colitis; 2022 Jan; 16(1):27-38. PubMed ID: 34402887
[TBL] [Abstract][Full Text] [Related]
22. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
[TBL] [Abstract][Full Text] [Related]
24. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S
Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507
[TBL] [Abstract][Full Text] [Related]
26. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
[TBL] [Abstract][Full Text] [Related]
27. Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Feagan BG; Rutgeerts P; Hanauer S; Colombel JF; Sands BE; Lukas M; Fedorak RN; Lee S; Bressler B; Fox I; Rosario M; Sankoh S; Xu J; Stephens K; Milch C; Parikh A;
N Engl J Med; 2013 Aug; 369(8):711-21. PubMed ID: 23964933
[TBL] [Abstract][Full Text] [Related]
28. Cannabis for the treatment of Crohn's disease.
Kafil TS; Nguyen TM; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012853. PubMed ID: 30407616
[TBL] [Abstract][Full Text] [Related]
29. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
[TBL] [Abstract][Full Text] [Related]
30. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
Sandborn WJ; Rutgeerts P; Gasink C; Jacobstein D; Zou B; Johanns J; Sands BE; Hanauer SB; Targan S; Ghosh S; de Villiers WJS; Colombel JF; Feagan BG
Aliment Pharmacol Ther; 2018 Jul; 48(1):65-77. PubMed ID: 29797519
[TBL] [Abstract][Full Text] [Related]
31. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
[TBL] [Abstract][Full Text] [Related]
32. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
[TBL] [Abstract][Full Text] [Related]
33. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
Hanauer SB; Sandborn WJ; Feagan BG; Gasink C; Jacobstein D; Zou B; Johanns J; Adedokun OJ; Sands BE; Rutgeerts P; de Villiers WJS; Colombel JF; Ghosh S
J Crohns Colitis; 2020 Jan; 14(1):23-32. PubMed ID: 31158271
[TBL] [Abstract][Full Text] [Related]
34. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
[TBL] [Abstract][Full Text] [Related]
35. Low dose naltrexone for induction of remission in Crohn's disease.
Parker CE; Nguyen TM; Segal D; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD010410. PubMed ID: 29607497
[TBL] [Abstract][Full Text] [Related]
36. Low dose naltrexone for induction of remission in Crohn's disease.
Segal D; Macdonald JK; Chande N
Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
[TBL] [Abstract][Full Text] [Related]
37. Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study.
Rosh JR; Turner D; Griffiths A; Cohen SA; Jacobstein D; Adedokun OJ; Padgett L; Terry NA; O'Brien C; Hyams JS
J Crohns Colitis; 2021 Nov; 15(11):1931-1942. PubMed ID: 34037715
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
39. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
40. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
Papp KA; Weinberg MA; Morris A; Reich K
Lancet; 2021 Apr; 397(10284):1564-1575. PubMed ID: 33894834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]